News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Andromeda Announces Successful Interim Results of Leading Product DiaPep 227 for Treatment of Type 1 Diabetes



6/25/2008 7:35:47 AM

Rehovot, Israel, June 23rd 2008 - Andromeda Biotech, a wholly owned subsidiary of CBI, focused on the development of innovative treatment for autoimmune diabetes, announced the successful results from the Interim Analysis of safety and efficacy data from the phase III clinical study conducted with DiaPep277, the company's lead product for the treatment of type 1 diabetes.

Read at NewsRx


comments powered by Disqus
NewsRx
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES